Literature DB >> 18479901

Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.

Mee Young Hong1, Navindra P Seeram, David Heber.   

Abstract

Prostate cancer is dependent on circulating testosterone in its early stages and is treatable with radiation and surgery. However, recurrent prostate tumors advance to an androgen-independent state in which they progress in the absence of circulating testosterone, leading to metastasis and death. During the development of androgen independence, prostate cancer cells are known to increase intracellular testosterone synthesis, which maintains cancer cell growth in the absence of significant amounts of circulating testosterone. Overexpression of the androgen receptor (AR) occurs in androgen-independent prostate cancer and has been proposed as another mechanism promoting the development of androgen independence. The LNCaP-AR cell line is engineered to overexpress AR but is otherwise similar to the widely studied LNCaP cell line. We have previously shown that pomegranate extracts inhibit both androgen-dependent and androgen-independent prostate cancer cell growth. In this study, we examined the effects of pomegranate polyphenols, ellagitannin-rich extract and whole juice extract on the expression of genes for key androgen-synthesizing enzymes and the AR. We measured expression of the HSD3B2 (3beta-hydroxysteroid dehydrogenase type 2), AKR1C3 (aldo-keto reductase family 1 member C3) and SRD5A1 (steroid 5alpha reductase type 1) genes for the respective androgen-synthesizing enzymes in LNCaP, LNCaP-AR and DU-145 human prostate cancer cells. A twofold suppression of gene expression was considered statistically significant. Pomegranate polyphenols inhibited gene expression and AR most consistently in the LNCaP-AR cell line (P=.05). Therefore, inhibition by pomegranate polyphenols of gene expression involved in androgen-synthesizing enzymes and the AR may be of particular importance in androgen-independent prostate cancer cells and the subset of human prostate cancers where AR is up-regulated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479901      PMCID: PMC2610864          DOI: 10.1016/j.jnutbio.2007.11.006

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  50 in total

Review 1.  Chemoprevention of prostate cancer with finasteride.

Authors:  I Thompson; P Feigl; C Coltman
Journal:  Important Adv Oncol       Date:  1995

2.  Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk.

Authors:  S A Devgan; B E Henderson; M C Yu; C Y Shi; M C Pike; R K Ross; J K Reichardt
Journal:  Prostate       Date:  1997-09-15       Impact factor: 4.104

3.  p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells.

Authors:  B A Narayanan; O Geoffroy; M C Willingham; G G Re; D W Nixon
Journal:  Cancer Lett       Date:  1999-03-01       Impact factor: 8.679

Review 4.  Risk factors for prostate cancer.

Authors:  K J Pienta; P S Esper
Journal:  Ann Intern Med       Date:  1993-05-15       Impact factor: 25.391

5.  1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.

Authors:  X Y Zhao; L H Ly; D M Peehl; D Feldman
Journal:  Endocrinology       Date:  1997-08       Impact factor: 4.736

6.  In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice.

Authors:  Navindra P Seeram; Lynn S Adams; Susanne M Henning; Yantao Niu; Yanjun Zhang; Muraleedharan G Nair; David Heber
Journal:  J Nutr Biochem       Date:  2005-06       Impact factor: 6.048

7.  Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.

Authors:  Julia T Arnold; Hanh Le; Kimberly K McFann; Marc R Blackman
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-11-09       Impact factor: 4.310

8.  Prevention of N-nitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice.

Authors:  K L Khanduja; R K Gandhi; V Pathania; N Syal
Journal:  Food Chem Toxicol       Date:  1999-04       Impact factor: 6.023

9.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.

Authors:  J M Kokontis; N Hay; S Liao
Journal:  Mol Endocrinol       Date:  1998-07

10.  Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.

Authors:  Z Culig; J Hoffmann; M Erdel; I E Eder; A Hobisch; A Hittmair; G Bartsch; G Utermann; M R Schneider; K Parczyk; H Klocker
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  30 in total

1.  Chinese red yeast rice inhibition of prostate tumor growth in SCID mice.

Authors:  Mee Young Hong; Susanne Henning; Aune Moro; Navindra P Seeram; Yanjun Zhang; David Heber
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-28

2.  Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells.

Authors:  Yağmur Kiraz; Vidushi S Neergheen-Bhujun; Nawraj Rummun; Yusuf Baran
Journal:  Tumour Biol       Date:  2015-08-29

Review 3.  The strategies to control prostate cancer by chemoprevention approaches.

Authors:  Harold Ting; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-01-02       Impact factor: 2.433

4.  Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model.

Authors:  Vaqar Mustafa Adhami; Imtiaz Ahmad Siddiqui; Deeba N Syed; Rahul Kumar Lall; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2011-12-22       Impact factor: 4.944

Review 5.  Cancer chemoprevention by pomegranate: laboratory and clinical evidence.

Authors:  Vaqar Mustafa Adhami; Naghma Khan; Hasan Mukhtar
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

Review 6.  Pomegranate extracts and cancer prevention: molecular and cellular activities.

Authors:  Deeba N Syed; Jean-Christopher Chamcheu; Vaqar M Adhami; Hasan Mukhtar
Journal:  Anticancer Agents Med Chem       Date:  2013-10       Impact factor: 2.505

7.  Physicochemical, nutritional and antibacterial characteristics of the fruit of Bromelia pinguin L.

Authors:  Juan Fernando Pío-León; Gabriela López-Angulo; Octavio Paredes-López; Magdalena de Jesús Uribe-Beltrán; Sylvia Páz Díaz-Camacho; Francisco Delgado-Vargas
Journal:  Plant Foods Hum Nutr       Date:  2009-09       Impact factor: 3.921

8.  Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation.

Authors:  Nivedita Banerjee; Stephen Talcott; Stephen Safe; Susanne U Mertens-Talcott
Journal:  Breast Cancer Res Treat       Date:  2012-09-02       Impact factor: 4.872

9.  Effect of carrier type and spray drying on the physicochemical properties of powdered and reconstituted pomegranate juice (Punica Granatum L.).

Authors:  Shima Yousefi; Zahra Emam-Djomeh; S M Mousavi
Journal:  J Food Sci Technol       Date:  2010-12-25       Impact factor: 2.701

10.  Behavioral effects of Citrus limon and Punica granatum combinations in rats.

Authors:  Azra Riaz; Rafeeq Alam Khan
Journal:  Metab Brain Dis       Date:  2016-08-11       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.